| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 08/20/2002 | US6436435 Liposome formulation of 5 β steroids |
| 08/20/2002 | US6436431 Fortified rice bran food product and method for promoting cardiovascular health |
| 08/20/2002 | US6436406 Compositions and methods for reducing or controlling blood cholesterol, lipoproteins, triglycerides and atherosclerosis |
| 08/20/2002 | US6436401 Administering the combination of anti-glutamic acid decarboxylase (anti-gad) antibody and anti-insulin antibody in amount effective to treat or prevent diabetes |
| 08/20/2002 | US6436366 Detecton, treatment and monitoring the patient with poor wound healing ability due to diabetes based on measurement of the breakdown product of nitric oxide (no) in specimens taken from the patient under controlled conditions |
| 08/20/2002 | CA2098404C Improved humanized immunoglobulins |
| 08/20/2002 | CA2073983C Novel vitamin d analogues |
| 08/20/2002 | CA2071273C Tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
| 08/20/2002 | CA2068700C Active oxygen scavenger |
| 08/20/2002 | CA2006865C Humanized immunoglobulins and their production and use |
| 08/15/2002 | WO2002063308A2 Prediction of wound healing by urinary nitrate assay |
| 08/15/2002 | WO2002063038A1 Method for identifying compounds modulating reverse cholesterol transport |
| 08/15/2002 | WO2002063033A1 Screening method |
| 08/15/2002 | WO2002063006A2 Receptors and membrane-associated proteins |
| 08/15/2002 | WO2002063005A2 Lipid-associated molecules |
| 08/15/2002 | WO2002063004A2 G-protein coupled receptors |
| 08/15/2002 | WO2002062999A2 Proteins and nucleic acids encoding same |
| 08/15/2002 | WO2002062994A1 Nucleic acid expressed in the hypothalamus or muscle tissue in obese animals |
| 08/15/2002 | WO2002062840A1 INTERFERON-α INDUCED GENE |
| 08/15/2002 | WO2002062835A1 Nucleic acids and polypeptides for controlling food intake and/or body weight |
| 08/15/2002 | WO2002062833A2 Modified leptin with reduced immunogenicity |
| 08/15/2002 | WO2002062810A2 Linkable sialyl lewis x analogs |
| 08/15/2002 | WO2002062800A1 Bicyclic nitrogenous fused-ring compound |
| 08/15/2002 | WO2002062799A1 Aryl substituted alkylcarboxylic acids as hypocholesterolemic agents |
| 08/15/2002 | WO2002062798A2 Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose |
| 08/15/2002 | WO2002062795A2 Dihydropyrazolopyridine compounds and pharmaceutical use thereof |
| 08/15/2002 | WO2002062789A1 Pyrazole compounds useful as protein kinase inhibitors |
| 08/15/2002 | WO2002062788A1 Sulfonamide compounds, their preparation and use |
| 08/15/2002 | WO2002062777A2 Amino ceramide-like compounds and therapeutic methods of use |
| 08/15/2002 | WO2002062774A1 Thiazole derivatives for treating ppar related disorders |
| 08/15/2002 | WO2002062767A1 Novel quinazoline derivatives |
| 08/15/2002 | WO2002062750A1 Cannabinoid receptor ligands |
| 08/15/2002 | WO2002062342A1 A method for the treatment of heart failure |
| 08/15/2002 | WO2002062302A2 Steroidal derivatives |
| 08/15/2002 | WO2002062301A2 Method and composition for rejuvinating cells, tissues, organs, hair and nails |
| 08/15/2002 | WO2002062297A2 Methods and compositions for modulating gluconeogenesis using pgc-1 |
| 08/15/2002 | WO2002062212A2 A personal condition management system |
| 08/15/2002 | WO2002055071A8 Compositions and methods for regulating lipoproteins and hypercholesterolmia with limonoids flavonoids and tocotrienols |
| 08/15/2002 | WO2002047685A3 Nmda receptor agonist pharmaceutical compositions |
| 08/15/2002 | WO2002042429A3 Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants |
| 08/15/2002 | WO2002034753A3 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 08/15/2002 | WO2002032861A3 Orally active salts with tyrosine kinase activity |
| 08/15/2002 | WO2002030860A3 Ketone compounds and compositions for cholesterol management and related uses |
| 08/15/2002 | WO2002028866A3 Hydroxyesters of 7-desmethylrapamycin |
| 08/15/2002 | WO2002028821A3 Propionic acid derivatives with ppar-alpha activating properties |
| 08/15/2002 | WO2002028433A3 Use of a ppar delta activator in the treatment of diseases related to no inhibit ion or tnf inhibition |
| 08/15/2002 | WO2002026729A3 Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
| 08/15/2002 | WO2002022212A8 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 08/15/2002 | WO2002022160A3 The diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism |
| 08/15/2002 | WO2002013811A3 Compositions containing hypoglycemically active stilbenoids |
| 08/15/2002 | WO2001096307A3 Cycloalkyl alkanoic acids as integrin receptor antagonists |
| 08/15/2002 | WO2001064899A3 Nucleotide sequences encoding proteins that take part in the biosynthesis of l-serine, improved method for microbially producing l-serine, and genetically modified microorganism suitable for use in said method |
| 08/15/2002 | WO2001032222A9 Selective toxin expression in angiogenic endothelial cells |
| 08/15/2002 | WO2001013935A3 Modulation of the blood-brain barrier transporter for leptin |
| 08/15/2002 | US20020111493 Amidino compounds useful as nitric oxide synthase inhibitors |
| 08/15/2002 | US20020111488 Beta-substitued beta-aminoethyl phosphonate derivatives |
| 08/15/2002 | US20020111483 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position |
| 08/15/2002 | US20020111383 Ultrafine L-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same |
| 08/15/2002 | US20020111373 Thiadiazolidin-2,4-dione compound |
| 08/15/2002 | US20020111366 Therapy for brain disorders; strokes |
| 08/15/2002 | US20020111364 ABCA-1 elevating compounds |
| 08/15/2002 | US20020111353 Antiinflammatory agents; central nervous system disorders;antidiabgetic agents; rheumatic disorders |
| 08/15/2002 | US20020111350 Aryl fused azapolycyclic compounds |
| 08/15/2002 | US20020111335 Bactericides, bacteriostats |
| 08/15/2002 | US20020111333 Hypotensive agents; cardiovascular disorders |
| 08/15/2002 | US20020111332 Alpha-substituted beta-aminoethyl phosphonate derivatives |
| 08/15/2002 | US20020111315 Synergistic mixture with antilipemic agent |
| 08/15/2002 | US20020111306 DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof |
| 08/15/2002 | US20020110873 Process for the production of lipstatin and tetrahydrolipstatin |
| 08/15/2002 | US20020110858 Lymphocytic membrane proteins |
| 08/15/2002 | US20020110836 PD-L2 molecules: novel PD-1 ligands and uses therefor |
| 08/15/2002 | US20020110560 Lowering elevated post-prandial blood glucose levels in mammals by increasing incretin half-life comprising administering inhibitor of Dipeptidyl Peptidase (DP IV) or enzymes having DP-IV-like activity |
| 08/15/2002 | US20020110551 Administering to the individual therapeutically effective amount of human acid alpha-glucosidase at regular interval for therapy of glycogen storage disease type II |
| 08/15/2002 | CA2438221A1 Steroidal derivatives |
| 08/15/2002 | CA2437727A1 Methods and compositions for modulating gluconeogenesis using pgc-1 |
| 08/15/2002 | CA2437717A1 G-protein coupled receptors |
| 08/15/2002 | CA2437571A1 Receptors and membrane-associated proteins |
| 08/15/2002 | CA2437497A1 Lipid-associated molecules |
| 08/15/2002 | CA2437434A1 Method for identifying compounds modulating reverse cholesterol transport |
| 08/15/2002 | CA2437423A1 Nucleic acid expressed in the hypothalamus or muscle tissue in obese animals |
| 08/15/2002 | CA2437265A1 Modified leptin with reduced immunogenicity |
| 08/15/2002 | CA2437215A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof |
| 08/15/2002 | CA2436741A1 Aryl substituted alkylcarboxylic acids as hypocholesterolemic agents |
| 08/15/2002 | CA2436738A1 Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose |
| 08/15/2002 | CA2436465A1 Prediction of wound healing by urinary nitrate assay |
| 08/15/2002 | CA2435844A1 Method and composition for rejuvinating cells, tissues, organs, hair and nails |
| 08/15/2002 | CA2433439A1 Proteins and nucleic acids encoding same |
| 08/15/2002 | CA2432188A1 Thiazole derivatives for treating ppar related disorders |
| 08/15/2002 | CA2405524A1 A personal condition management system |
| 08/14/2002 | EP1231218A2 An appetite-suppressing peptide, its compositions and use |
| 08/14/2002 | EP1231212A1 Pharmaceutical compositions for the treatment of disorders of the CNS and other disorders |
| 08/14/2002 | EP1231211A1 Thiazolidinedione derivatives as antidiabetic agents |
| 08/14/2002 | EP1230928A1 Use of peptide |
| 08/14/2002 | EP1230920A1 Food materials useful in preventing and ameliorating metabolic bone diseases and preventives/remedies for metabolic bone diseases comprising these materials |
| 08/14/2002 | EP1230389A1 Antisense inhibition of pi3 kinase p55 gamma expression |
| 08/14/2002 | EP1230379A2 Regulating endogenous inhibitor at atp synthase |
| 08/14/2002 | EP1230369A2 Polypeptide hormone phosphatonin |
| 08/14/2002 | EP1230367A1 19 human secreted proteins |
| 08/14/2002 | EP1230360A2 15 human secreted proteins |
| 08/14/2002 | EP1230349A2 Nucleic acids encoding endotheliases, endotheliases and uses thereof |